Visual outcomes and anatomical biomarkers of Faricimab for diabetic macular edema in the J-CREST real-world comparison of naïve and treated eyes
Authors:
Open Access
- 21 October 2025
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-9
Abstract
We evaluated the real-world efficacy of intravitreal faricimab for diabetic macular edema (DME) and its relationship with visual and retinal anatomical changes using optical coherence tomography. We retrospectively assessed 174 patients (214 eyes) with DME from 13 Japan Clinical REtina Study Group (J-CREST) sites who received ≥ 1 faricimab injection and were followed ≥ 6 months, and compared treatment-naïve (with no prior anti-VEGF treatment) and previously treated groups. Both groups showed significant improvements in best-corrected visual acuity (BCVA) and central subfield thickness (CST BCVA gain was greater in the treatment-naïve group (p = 0.0109), whereas CST reduction showed little difference (p = 0.31). Resolution of cystoid macular oedema, diffuse retinal thickening, and subretinal fluid (SRF) was observed in both groups. Resolution of inner nuclear layer (INL) oedema and SRF significantly correlated with ≥ 0.2 log MAR BCVA improvement in the treatment-naïve group (p = 0.043 and p = 0.022, respectively). Mean number of injections was comparable between groups. One case of anterior chamber inflammation occurred; however, no serious systemic events were observed. In conclusion, faricimab significantly improved visual and anatomical outcomes in DME, especially in treatment-naïve eyes. Early resolution of INL oedema and SRF may serve as a potential biomarker for visual prognosis.Keywords
This publication has 26 references indexed in Scilit:
- Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedemaEye, 2024
- Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in diabetic macular edema: 2-year results from the Japan subgroup of the phase 3 YOSEMITE trialJapanese Journal of Ophthalmology, 2024
- Switch to faricimab after initial treatment with aflibercept in eyes with diabetic macular edemaInternational Ophthalmology, 2024
- Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomesGraefe's Archive for Clinical and Experimental Ophthalmology, 2024
- Therapeutic implication of human placental extract to prevent liver cirrhosis in rats with metabolic dysfunction-associated steatohepatitisClinical Science, 2024
- Conversion to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular oedemaBritish Journal of Ophthalmology, 2024
- Association between Aqueous Humor Cytokines and Structural Characteristics Based on Optical Coherence Tomography in Patients with Diabetic Macular EdemaJournal of Ophthalmology, 2023
- Outcomes of Over 40,000 Eyes Treated for Diabetic Macula Edema in Routine Clinical Practice: A Systematic Review and Meta-analysisAdvances in Therapy, 2022
- IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMARetina, 2018
- VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB DEPENDS ON THE OPTICAL COHERENCE TOMOGRAPHIC PATTERNS OF PATIENTS WITH DIFFUSE DIABETIC MACULAR EDEMARetina, 2013